Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Expenses: 2010-2025

Historic Operating Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $46.6 million.

  • Ironwood Pharmaceuticals' Operating Expenses fell 29.38% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year decrease of 22.71%. This contributed to the annual value of $258.3 million for FY2024, which is 81.39% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Operating Expenses stood at $46.6 million, which was up 16.68% from $39.9 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Operating Expenses high stood at $1.2 billion for Q2 2023, and its period low was $38.6 million during Q3 2021.
  • In the last 3 years, Ironwood Pharmaceuticals' Operating Expenses had a median value of $66.0 million in 2024 and averaged $163.9 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Operating Expenses soared by 2,763.48% in 2023, and later tumbled by 94.17% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Operating Expenses (Quarterly) stood at $60.5 million in 2021, then crashed by 35.85% to $38.8 million in 2022, then surged by 105.90% to $80.0 million in 2023, then dropped by 26.15% to $59.1 million in 2024, then decreased by 29.38% to $46.6 million in 2025.
  • Its Operating Expenses was $46.6 million in Q3 2025, compared to $39.9 million in Q2 2025 and $70.3 million in Q1 2025.